The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Inter-reader reliability of immune-specific response criteria (irRECIST & iRECIST).
 
Kathleen Ruchalski
No Relationships to Disclose
 
Hyun J. Kim
Consulting or Advisory Role - MedQIA; MedQIA
Research Funding - Boehringer Ingelheim; Genentech
Patents, Royalties, Other Intellectual Property - Quantitative interstitial score and system
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Rohit Dewan
No Relationships to Disclose
 
Michael Douek
No Relationships to Disclose
 
Victor Sai
No Relationships to Disclose
 
Bianca Villegas
No Relationships to Disclose
 
Koon-Pong Wong
No Relationships to Disclose
 
Aaron E. Lisberg
Employment - Boston Scientific (I)
Stock and Other Ownership Interests - Boston Scientific (I)
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Jazz Pharmaceuticals; Leica Biosystems; Lilly; MorphoSys; Novartis; Novocure; Oncocyte; Pfizer; Sanofi/Regeneron
Research Funding - AstraZeneca; Calithera Biosciences; Daiichi Sankyo; Dracen; WindMIL
 
Jonathan W. Goldman
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Pfizer
Research Funding - Abbvie (Inst); Advaxis (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Jonathan Goldin
Consulting or Advisory Role - Boehringer Ingelheim
Speakers' Bureau - Boehringer Ingelheim; Genentech; Olympus; Roche
 
Edward B. Garon
Consulting or Advisory Role - ABL Bio; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Gilead Sciences; GlaxoSmithKline; Lilly; Merck; Natera; Novartis; Personalis; Sanofi/Regeneron; Shionogi; Xilio Therapeutics
Research Funding - ABL Bio (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Diagnosistic and therapeutic use of "Motif Neoepitopes" as defined by Cummings et al in Nature Cancer. (Inst)
 
Denise R. Aberle
No Relationships to Disclose